Table 2. The differences of serum IL-9 levels in various clinical factors.

Factors	No.	Average	Range	P value
Gender
Male	56	7.02	1.38–51.87	0.316
Female	18	4.78	1.62–23.52
Age
≤60	63	5.71	1.38–51.87	0.042
>60	11	10.85	2.08–32.4
ECOG performance status
0	28	4.61	1.38–22.8	0.125
1–2	46	7.61	1.62–51.87
B symptoms
Absent	35	4.1	1.38–22.8	0.009
Present	39	8.61	1.62–51.87
Serum LDH
Normal	51	5.61	1.62–32.4	0.995
>normal	23	8.39	1.38–51.87
LN involvement
Absent	35	4.98	1.38–32.4	0.011
Present	39	7.82	1.66–51.87
Ann Arbor stage
I	32	5.17	1.38–32.4	0.084
II	30	7.76	1.62–51.87
III–IV	12	6.74	1.69–24.82
IPI
0–1	62	6.38	1.38–51.87	0.125
2–5	12	6.99	2.62–24.82
KPI
0	15	5.16	1.38–32.4	0.284
1	27	5.74	1.62–29.28
2	16	4.59	1.66–11.12
3–4	16	10.84	1.69–51.87
Lymphocytes
Normal	51	7.56	1.38–51.87	0.25
<normal	23	4.07	1.62–23.52
Monocytes
Normal	33	6.4	1.38–32.4	0.724
>normal	41	6.54	1.62–51.87

Abbreviations: ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase;

LN, local lymph node; IPI, international prognostic index; KPI, Korean prognostic index.